Head-to-head evidence
LY01008 vs Vegzelma (bevacizumab-adcd)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: VEGF-A · full Non-Small Cell Lung Cancer pipeline
LY01008
Developed by Luye Pharma Group
NCT03533127 · Phase 3 · status unknown
This was a randomized, double-blind, active-controlled equivalence trial in 648 patients that measured objective tumor response rate, using the same paclitaxel/carboplatin backbone in both arms. LY01008's response rate was statistically equivalent to bevacizumab's, within the prespecified margin, meeting the trial's own equivalence criterion.
Vegzelma (bevacizumab-adcd)
Marketed by Celltrion
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: LY01008's landscape · Vegzelma (bevacizumab-adcd)'s landscape